Previous 10 | Next 10 |
Image source: The Motley Fool. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) Q4 2021 Earnings Call Feb 23, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2021 Earn...
The following slide deck was published by Maravai LifeSciences Holdings, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Maravai LifeSciences Holdings, Inc. 2021 Q4 - Results - Earnings Call Presentation
Maravai LifeSciences Holdings press release (NASDAQ:MRVI): Q4 GAAP EPS of $0.42 beats by $0.08. Revenue of $228.44M (+132.3% Y/Y) beats by $20.35M. Shares +4.31%. For further details see: Maravai LifeSciences Holdings GAAP EPS of $0.42 beats by $0.08, revenue of $228.44M beats by $20.35...
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and the full year ended Decem...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperformed the benchmark in the fourth qua...
Bruker Corporation has been performing exceptionally well as of late, driven by strong sales growth and an increase in profits. However, it's uncertain whether recent moves higher on its top and bottom lines are here to stay. At best, shares look to be fairly valued, with the poss...
Don't think that the current malaise for biotech investors will last forever. There are some biotech stocks that have tremendous long-term potential. We asked three Motley Fool contributors to identify biotech stocks they think could deliver 5x returns by 2030. Here's why they chose C...
MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities serving the high-growth cell and gene therapy market SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ...
R&D Day - January 28, 2022 Q4 Earnings Conference Call - February 23, 2022 SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, will ho...
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it had successfully completed the repricing of its existing cred...
News, Short Squeeze, Breakout and More Instantly...
Maravai LifeSciences Holdings Inc. Company Name:
MRVI Stock Symbol:
NASDAQ Market:
Maravai LifeSciences Holdings Inc. Website:
2024-07-25 20:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on...
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important for Maravai and our stakeholders. - Increased the sc...